Artiva Biotherapeutics, Inc. Share Price & Technical Analysis
ARTV · $7.87 (-1.50%)
Healthcare / Biotechnology
$7.87
-1.50%
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, r…
Price chart
Seasonality
May has 0 positive and 2 negative years (last 3 years shown)
-23% return in May, -21% avg return in past 3 year May month.
94% return in 2026, -19% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -9% | 53% | 16% | 57% | -23% | – | – | – | – | – | – | – | 94% |
| 25 | -49% | -18% | -29% | -25% | -21% | -25% | 100% | 10% | -9% | 50% | -10% | 16% | -8% |
| 24 | – | – | – | – | – | – | -26% | -3% | 33% | -34% | 23% | -22% | -29% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$519.41M
P/E ratio
—
52W high
$14.53
52W low
$1.47
Volume
3,09,495
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Artiva Biotherapeutics, Inc. share price today?
- Artiva Biotherapeutics, Inc. (ARTV) last traded around $7.87 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ARTV have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ARTV. Download the app for real-time alerts.
- How can I analyze Artiva Biotherapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.